Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) Short Interest Down 25.0% in October

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) was the recipient of a significant decrease in short interest during the month of October. As of October 15th, there was short interest totalling 79,900 shares, a decrease of 25.0% from the September 30th total of 106,500 shares. Currently, 6.1% of the shares of the stock are short sold. Based on an average daily volume of 175,500 shares, the short-interest ratio is currently 0.5 days.

Sonoma Pharmaceuticals Stock Down 3.3 %

Shares of SNOA traded down $0.10 during midday trading on Tuesday, hitting $2.90. The company’s stock had a trading volume of 22,868 shares, compared to its average volume of 162,725. Sonoma Pharmaceuticals has a one year low of $2.32 and a one year high of $9.37. The stock has a market capitalization of $2.78 million, a price-to-earnings ratio of -0.28 and a beta of 1.37. The company’s fifty day simple moving average is $2.76 and its two-hundred day simple moving average is $1.13.

Sonoma Pharmaceuticals (NASDAQ:SNOA) last released its earnings results on Thursday, August 8th. The company reported ($0.07) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.01). The business had revenue of $3.39 million during the quarter. Sonoma Pharmaceuticals had a negative net margin of 35.91% and a negative return on equity of 65.66%. On average, research analysts predict that Sonoma Pharmaceuticals will post -4 earnings per share for the current year.

About Sonoma Pharmaceuticals

Sonoma Pharmaceuticals, Inc, develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis.